Cargando…

Real‐world GLP‐1 RA therapy in type 2 diabetes: A long‐term effectiveness observational study

AIMS: To evaluate in a real‐world setting the effectiveness and tolerability of available GLP‐1 RA drugs in patients with type 2 diabetes after a prolonged follow‐up. MATERIALS AND METHODS: Observational, retrospective, single‐centre study in patients starting GLP‐1 RA therapy. Change in HbA1c, fast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tofé, Santiago, Argüelles, Iñaki, Mena, Elena, Serra, Guillermo, Codina, Mercedes, Urgeles, Juan Ramón, García, Honorato, Pereg, Vicente
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354754/ https://www.ncbi.nlm.nih.gov/pubmed/30815578 http://dx.doi.org/10.1002/edm2.51

Ejemplares similares

Age-standardized incidence, mortality rate, and trend changes of thyroid cancer in the Balearic Islands during the 2000–2020 period: a population-based study
por: Tofé, Santiago, et al.
Publicado: (2023)

Glycemic Control Following GLP-1 RA or Basal Insulin Initiation in Real-World Practice: A Retrospective, Observational, Longitudinal Cohort Study
por: Peng, Xuejun Victor, et al.
Publicado: (2020)

Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study
por: Lingvay, Ildiko, et al.
Publicado: (2021)

SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
por: Anson, Matthew, et al.
Publicado: (2023)

Ranizurel safety evaluation in real-world -(RaSER) study
por: Sharma, Ashish, et al.
Publicado: (2022)

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study
por: Knudsen, Jakob S., et al.
Publicado: (2020)

Hypocalcemia due to 22q11.2 deletion syndrome diagnosed in adulthood
por: Cabrer, Maria, et al.
Publicado: (2018)

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study
por: Kim, Minyoung, et al.
Publicado: (2023)

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
por: Lisco, Giuseppe, et al.
Publicado: (2022)

Comparative cardiovascular effects of GLP‐1 agonists using real‐world data
por: Wallia, Amisha, et al.
Publicado: (2023)

Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain
por: Norrbacka, Kirsi, et al.
Publicado: (2021)

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

GLP-1 RA Improves Diabetic Retinopathy by Protecting the Blood-Retinal Barrier through GLP-1R-ROCK-p-MLC Signaling Pathway
por: Wei, Liufeng, et al.
Publicado: (2022)

Periprocedural Direct Oral Anticoagulant Management: The RA-ACOD Prospective, Multicenter Real-World Registry
por: Ferrandis, Raquel, et al.
Publicado: (2020)

CAPTURING REAL-WORLD LOSSES OF BALANCE AND RECOVERY RESPONSES IN OLDER ADULTS AT RISK FOR FALLS
por: Alexander, Neil, et al.
Publicado: (2019)

GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries
por: Divino, Victoria, et al.
Publicado: (2017)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

Health care utilization and costs associated with switching from DPP-4i to GLP-1RA or SGLT2i: an observational cohort study
por: Newman, Terri Victoria, et al.
Publicado: (2021)

Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA Study)
por: Hernández-Cruz, Blanca, et al.
Publicado: (2022)

Glycemic monitoring with once-weekly Glucagon-like peptide 1 receptor agonist (GLP1RA) use
por: Kalra, Sanjay, et al.
Publicado: (2015)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
por: Xiang, Jie, et al.
Publicado: (2023)

MON-LB028 Comparing Cardiovascular Effects of GLP-1 Agonists in a Real World Setting
por: Wallia, Amisha, et al.
Publicado: (2019)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

Correction to: Real-world Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis patients in Spain: Results of a multicenter, observational study in routine clinical practice (The ORBIT-RA Study)
por: Hernández-Cruz, Blanca, et al.
Publicado: (2022)

Real‐world outcomes of addition of insulin glargine 300 U/mL (Gla‐300) to glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) therapy in people with type 2 diabetes: The DELIVER‐G study
por: Bailey, Timothy S., et al.
Publicado: (2022)

Real-World Use of Generic Meropenem: Results of an Observational Study
por: Garnica-Velandia, Santiago, et al.
Publicado: (2021)

Glucagon-Like Peptide 1 Receptor Agonist (GLP1RA) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
por: Caparrotta, Thomas M., et al.
Publicado: (2021)

Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
por: Kalra, Sanjay, et al.
Publicado: (2019)

FRAILTY AND THE COMPARATIVE EFFECTIVENESS AND SAFETY OF SGLT2I AND GLP1-RA IN OLDER ADULTS WITH TYPE 2 DIABETES
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study
por: Zhou, Yu, et al.
Publicado: (2022)

Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
por: Blonde, Lawrence, et al.
Publicado: (2018)

Ra : una balsa de papyrus a través del Atlántico /
por: Genovés, Santiago
Publicado: (1990)

P1635: REAL-WORLD DATA OF THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RA) USE IN IMMUNE THROMBOCYTOPENIA (ITP)
por: Dangudubiyyam, S., et al.
Publicado: (2022)

Practical Haskell: a real world guide to programming
por: Mena, Alejandro Serrano
Publicado: (2019)

Elevated Circulating Fetuin-B Levels Are Associated with Insulin Resistance and Reduced by GLP-1RA in Newly Diagnosed PCOS Women
por: Mokou, Mani, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fl1ql9l3r28thg8rk90qculi1n